Helicobacter pylori (H. pylori ) eradication can reduce gastric cancer. However, gastric cancer still develops after eradication, and cases who received eradication therapy are increasing. In this study, we have reviewed the characteristics and predictors of primary gastric cancer developing after H. pylori eradication. In terms of the characteristics, endoscopic, histologic, and molecular characteristics are reported. Endoscopically, gastric cancer after eradication is often depressedtype and shows a gastritis-like appearance, which sometimes makes the diagnosis difficult. Histologically, most gastric cancer after eradication is intestinal type, and non-neoplastic epithelium, also called epithelium with low-grade atypia, is frequently seen over the tumor, which is presumably the cause of the endoscopic gastritis-like appearance. As for molecular characteristics, some markers, such as Ki67, MUC2, and Wnt5a expression, are lower in cancer from patients in whom H. pylori has been eradicated. In terms of predictors, several Japanese studies have reported that severe endoscopic atrophy at eradication is a risk factor for gastric cancer development. Histologic intestinal metaplasia, especially in the corpus, and long-term use of proton pump inhibitors, are also reported as risk factors for gastric cancer after H. pylori eradication. These studies on the characteristics and predictors of gastric cancer development will become the cornerstone for establishing a novel surveillance program based on the gastric cancer risk stratification specific to H. pylori -eradicated patients. rates of gastric cancer detected after eradication are increasing and this is becoming an important clinical issue. We review the characteristics and predictors of primary gastric cancer after H. pylori eradication, and discuss the risk stratification of gastric cancer after eradication.
INTRODUCTION
Gastric cancer is one of the deadliest malignancies, with 1 million cases annually around the world. In the past, the standard curative treatment was surgical resection with lymph node dissection, as the disease was usually diagnosed in the advanced stages in symptomatic subjects. To improve the prognosis of gastric cancer, diagnostic instruments and techniques were developed in Japan, where the occurrence of, and mortality by, gastric cancer were extremely high. Surveillance by endoscopy is one of the methods that enable early diagnosis of gastric cancer. Not only through diagnosis but also by its therapeutic properties [1] endoscopy has changed the management, and improved the pro gnosis, of gastric cancer. The discovery of the gastric pathogen, Helicobacter pylori (H. pylori), which was recognized as a group 1 carcinogen [2] , dramatically changed the image of gastric cancer from a cryptogenic devastating disease to an infectious, predictable and preventable one [3] . Warren and Marshall isolated H. pylori from gastric tissue with gastritis [4] . Initially the pathogenesis of this bacterium was examined in peptic ulcer patients. Developments of diagnostic procedures and antibiotics for H. pylori have improved the treatment of peptic ulcers [57] . Further research on this pathogen revealed its pathogenesis in relation to chronic gastritis and gastric cancer as well, with early studies demonstrating that H. pylori infection increased the risk for gastric cancer [8, 9] . Uemura et al [10] performed a cohort study of endoscopic surveillance of gastric cancer and found that all occurrences of gastric cancer in the cohort were in H. pylori-infected subjects. From these findings, H. pylori infection was incorporated into the previously proposed gastric carcinogenesis process known as Correa's cascade [1113] . Specifically, H. pylori infection initiates sequential histological changes such as non atrophic gastritis, atrophic gastritis [1416] , intestinal metaplasia [1518] , dysplasia, and intestinaltype gastric cancer [19] . In contrast, such a sequential model was not applicable to diffusetype gastric cancer, though diffusetype gastric cancer is also associated with H. pylori infection [2022] .
Based on these findings, other studies examined the effect of H. pylori eradication on preventing gastric cancer. Fukase et al [23] reported that metachronous development of gastric carcinoma was reduced by H. pylori eradication after endoscopic resection of early gastric cancer in an openlabel multicenter randomized controlled trial. Wong et al [24] performed a prospective, randomized, placebocontrolled, populationbased study to examine the association of primary gastric cancer and eradication therapy. The incidence of gas tric cancer development was similar between the eradicationtreatment group and placebo group in this study. However, in the subgroup without precancerous lesions, eradication significantly decreased the de velopment of gastric cancer. Recent systematic re views and metaanalysis showed reduction of primary and metachronous gastric cancer by H. pylori eradi cation [2527] . Although the effect of H. pylori eradication on the prognosis is not determined yet, it is expected that H. pylori eradication and elimination within society will lead to less gastric cancer cases and a reduction of medical costs [28] . These reports on the effect of H. pylori eradication for gastric cancer also elucidated another important fact. That is, gastric cancer did develop in H. pylori eradicated patients [29, 30] , not only in gastric cancer treated patients, who presumably possess the highest risk, but also in gastriccancer naïve cases [24, 31] . Time from eradication to cancer occurrence varied from se veral months to more than 10 years [31, 32] . Therefore, identification of high-risk subjects, who would benefit from extensive surveillance, is an important clinical problem. Many earlier studies have investigated dif ferences in gastric cancers that developed in H. pyloriinfected and eradicated patients, to assist the early and accurate diagnosis in eradicated cases. Recent studies, which included a relatively large number of H. pylorieradicated cohorts, enabled analysis of the risk factors of future gastric cancer development.
The purpose of this review article was to summarize the characteristics of gastric cancer that developed after H. pylori-eradication therapy, and also to identify the predictors of primary gastric cancer. Many previous studies have examined risk factors for metachronous gastric cancer development, in followup or cross sectional studies of endoscopically removed gastric cancer cases [3337] . Because these cohorts had already developed gastric cancer, they benefited from mul tiple, surveillance endoscopy as well as H. pylori eradi cation. There are many review articles on this specific topic [3840] . However, these patients who once had gastric cancer are highrisk patients anyway, and close followup should be required. In contrast, a review article for the risk factors in gastriccancer naïve cases after H. pylori eradication, which would be valuable for stratifying huge numbers of H. pylorieradicated patients according to gastric cancer risk, has not been conducted thus far. The findings of this article will be useful for establishing a proper followup strategy for H. pylorieradicated subjects.
ENDOSCOPIC AND HISTOLOGICAL CHARACTERISTICS OF GASTRIC CANCER AFTER H.PYLORI ERADICATION

Endoscopic features
Many studies have examined the endoscopic findings of primary gastric cancer after H. pylori eradication.
Most of these studies were derived from early gastric cancer cases who underwent endoscopic treatment and, therefore, potentially include selection bias. [41] . In a recent and relatively large propensity score matching study of endoscopic submucosal dissection cases, 81% (78 of 96) of early gastric cancers from H. pylori-eradicated patients were depressed type, a significantly higher proportion than the 53% (51 of 96) in H. pylori-positive cases [42] . Many other studies, including case series [43] , or case control studies [44, 45] also indicated predominance of depressed or ulcer type (0Ⅱc) gastric cancer in H. pylori-eradicated cases (Table 1) .
Gastritis like appearance:
Another important charac teristic of gastric cancer after H. pylori eradication is its gastritislike appearance. This was initially reported by Kobayashi et al [46] . A "gastritislike" appearance under narrowband imaging with magnifying endoscopy was characterized by uniform papillae and/or tubular pits with a whitish border, regular or faint microvessels, and unclear demarcation, resembling the adjacent noncancerous mucosa (Figure 1 ). They examined re trospectively, differentiatedtype early gastric cancer of 50 lesions after eradication, and 50 lesions without eradication. A "gastritislike" appearance was more frequent for the eradication group (22/50) than the control group (2/50), and the "gastritislike" appearance correlated with histological surface differentiation [46] . They also reported that the development of "gastritis like" appearance was associated with less endoscopic atrophy [47] . These phenotypic characteristics or changes make the diagnosis of gastric cancer after H. pylori eradication difficult. In fact, it is reported that utilization of chromoendoscopy did not improve the diagnostic Number of gastric cancer after eradication/during infection
Study design Case recruitment Characteristics
Shichijo et al [31] 21/NA Case series Surveillance Intestinal type Maehata et al [42] 96/96
Propensity scorematched study
ESD cases Depressed
Nishizawa et al [43] 34/NA Case series Surveillance Depressed, intestinal type, relatively small Matsuo et al [44] 26/78
Case control study Surveillance Male, intestinal type, flat-depressed, low MUC2 and Wnt5a Yamamoto et al [45] 18/36
Case control study Early stage cancer Smaller, lower Ki-67 index, depression, complete gastric type or gastric predominant mixed type Horiguchi et al [48] 71/115
Case control study Case series Non-tumorous epithelium Surface differentiation Ito et al [52] 29/NA Case series ESD cases Normal columnar epithelium Kitamura et al [53] 27/27
Case control study Endoscopic resection cases Low-grade atypia on the surface Hori et al [54] 59/152
Case control study Endoscopic resection cases Non-neoplastic epithelium, flattening of tumors, muting of the whitish discoloration NA: Not applicable; ESD: Endoscopic submucosal dissection.
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Other: One study evaluated Ki67 staining, which is a molecular indicator of cell proliferation. The Ki67 index was lower in the eradicated group than in the non eradicated group. Immunohistochemical phenotyping revealed that gastric cancer after eradication was more often gastricpredominant type [45] . Another study investigated mucus patterns and Wnt5a expression in gastric cancer specimens derived from H. pylori eradicated and infected patients. The result showed MUC2 and Wnt5a expressions were significantly lower in gastric cancers from H. pylorieradicated patients [44] .
PREDICTORS OF PRImARy GASTRIC CANCER AFTER H. PYLORI ERADICATION
In this section, we summarize risk factors for gastric cancer development after H. pylori eradication. There are several cohort studies [31, 32, 5558] and casecontrol studies [5963] on this topic (Table 2 ). These studies have examined patients' characteristics, endoscopic features, and histological findings associated with gastric cancer after H. pylori eradication.
Endoscopic gastric atrophy
The classification of endoscopic atrophy was first des cribed by Kimura and Takemoto in 1969 to discriminate the histological border between the pyloric and fundic glands [64] . They found a close association between this boundary and gastritis. Later, Uemura et al. showed, in their important report, which indicated the critical involvement of H. pylori in gastric carcinogenesis, that severe endoscopic atrophy was a risk factor for primary gastric cancer development in H. pyloriinfected cases [10] . As for patients in whom H. pylori had been eradi cated, Take et al. investigated risk factors associated with gastric cancer development in 1674 H. pylorieradicated peptic ulcer patients [32] . In their mean 5.6year surveillance endoscopy program following H. pylori eradication, they found 28 cases of gastric cancer in patients with a mean age of 51 years. Patients with severe endoscopic gastric atrophy, which they defined as KimuraTakemoto classification O2 and O3, before eradication had increased risk for gastric cancer (0.62% per year), compared to patients with mild (C1 and C2) and moderate (C3 and O1) atrophy (0.04% and 0.28% per year, respectively). We also examined endoscopic atrophy for the predi ction of gastric cancer in the abovementioned study [31] . Multivariate analysis revealed that histologic intestinal metaplasia and severe endoscopic atrophy are indepen dent risks for gastric cancer development. In our study, patients with O2 or O3 atrophy at eradication had 9.3fold risk for developing gastric cancer compared to patients with no or mild atrophy (C0C2) in multivariate analysis. Many other cohort studies [55, 56] and case control studies [59, 60] showed similar results, that severe endoscopic atrophy is associated with gastric cancer development in H. pylori-eradicated patients ( Table 2) . reliability of gastric cancer after H. pylori eradication [48] . These endoscopic characteristics of gastric cancer after eradication were associated with histological features that have been termed "nonneoplastic epithelium" (Discussed in the following chapter).
Other: Smaller tumor size is also reported as a charac teristic of gastric cancer in H. pylori-eradicated cases. Yamamoto et al [45] reported that the average diameter of gastric cancer detected after successful eradication was smaller than that in noneradicated, age, sex, and cancerdepth matched controls. However the control group did not undergo the routine followup examination that was performed in the eradicated group. Another propensitymatched study indicated similar tumor size in H. pylorieradicated and infected patients [42] .
Histology
Other characteristics of gastric cancer detected after H. pylori eradication by histological assessment.
Intestinal type:
We have previously conducted a co hort study of 573 H. pylori-eradicated cases. During the 6.2 ± 4.8 years of the observation period, we found 21 cases of primary gastric cancer in these H. pylorieradicated patients [31] . Among the 21 tumors, 20 (95%) were intestinaltype gastric cancer, while only one was diffuse type. We did not compare those cancers with noneradicated cases; however, before eradication therapy, the numbers of intestinal and diffusetype gas tric cancers were roughly even [49] . We speculate that Helicobacter eradication could lead to the dominance of intestinaltype gastric cancer. This intestinaltype dominance (i.e., diffusetype reduction) was also re ported in other studies [35, 50, 51] . However, several studies did not show differences in histological type between H. pylori-eradicated and noneradicated cases [42, 45] . These studies analyzed only endoscopic treatment cases, which inevitably exclude diffusetype cancers. This reduction of diffusetype gastric cancer by H. pylori eradication will be clarified in future large-scale analysis.
Non-neoplastic epithelium:
This histological character istic was initially described in a study that evaluated the histological change of gastric tumors after Helicobacter pylori eradication [52] . They named nonneoplastic epi thelium which often appeared on the surface of gastric cancer after eradication as epithelium with lowgrade atypia (ELA). ELA was observed in 22 out of 27 gastric cancer cases detected after successful eradication where gastrictype mucin was frequently expressed [53] . Hori et al. compared 59 tumors detected after eradication and 152 detected while infected, and showed that the histological length ratio of nonneoplastic epithelium to the tumor was 8% for the eradicated group, and 0% for the infected group. The extension of nonneoplastic epithelium has been reported in several other studies (Table 1 ) [48, 54] .
Histological intestinal metaplasia
Another wellcharacterized gastric cancer risk is his tological intestinal metaplasia, evaluated at the time of eradication therapy (Figure 2 ). It has been suggested that intestinal metaplasia precedes gastric cancer de velopment, especially for intestinaltype cancer [11, 13] . There have been debates on whether this histological change is a precancerous or a paracancerous lesion, which has not yet been completely clarified. Nonetheless, several observational studies have indicated that the presence of intestinal metaplasia in the background gastric tissue indicates a higher risk for accompanying or developing gastric cancer [10, 17, 18, 65, 66] . As described above, we have analyzed 573 endos copybased surveillance cases after H. pylori eradiation, in which 21 cases of gastric cancer were observed [31] . Before eradication, participants had been evaluated for the presence of intestinal metaplasia [17, 18] and neutrophil infiltration using antral and corpus biopsies, and the degree of endoscopic atrophy. We classified patients into three groups according to the histological metaplasia distribution [17, 18] . Compared to the group with no intes tinal metaplasia, patients with metaplasia limited to antrum had a 4.5fold increased risk, and patients with metaplasia in corpus had a 7.6fold increased risk in univariate analysis. Multivariate analysis revealed that the presence of histologic intestinal metaplasia was an independent risk for gastric cancer development. To the best of our knowledge this is the first report that shows intestinal metaplasia as the predictor of future gastric cancer after H. pylori eradication.
Kodama et al [59] performed crosssectional and casecontrol analyses of an H. pylori-eradicated cohort and reported that the histological intestinal metaplasia score in the corpus was significantly higher in gastric cancer cases than that in age and sex matched non cancer controls. This study also evaluated the intestinal metaplasia score in the antrum, which did not show a statistical difference between the two groups. Taken together, the presence of intestinal metaplasia, espe cially in the corpus, might indicate a higher risk for de veloping gastric cancer. 
Risk factor
Shichijo et al [31] 573 Cohort study CG/DU/GU 58 6.4 21 Endoscopic severe atrophy Histologic intestinal metaplasia Take et al [32] 1674
Cohort study GU/DU 51 5.6 28 Endoscopic severe atrophy Toyoshima et al [55] 1232
Cohort study CG/DU/GU 54 2.5 15 Endoscopic severe atrophy Sakitani et al [56] 965
Cohort study CG/DU/GU 63 4.5 21 Endoscopic severe atrophy Cheung et al [57] 63397
Cohort study Helicobacter pylori infection (GU 2%, DU 3%) 55 7.6 153 Proton pump inhibitor Takata et al [58] 101 Cohort study CG/GU/GC 56 5.3 8 Age Kodama et al [59] 2355 Matched control study CG/DU/GU/GC 63 4.1 21 Endoscopic severe atrophy OLGA staging Histologic atrophy at the antrum Histologic inflammation at the corpus Histologic intestinal metaplasia at the corpus Sugimoto et al [60] 1200 Cross-sectional study NA 70 4.6 79 Endoscopic severe atrophy Haneda et al [62] 261 Cross sectional study CG/DU/GU/GC/ MALToma/hyperplastic polyp 57 NA 47 Pepsinogen Ⅰ/Ⅱ ratio ≤ 4.5
Maeda et al [63] 177 ; C: Microscopic picture of a biopsy specimen with intestinal metaplasia (HE, orig. mag. ×100).
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Long-term use of proton pump inhibitors
Cheung et al [57] recently reported, based on a territory wide health database of Hong Kong, that long term use of proton pump inhibitors (PPI) was associated with an increased gastric cancer risk in subjects after H. pylori-eradication therapy. Among 63397 eligible patients who received clarithromycinbased triple ther apy between 2003 and 2012, 153 cases of gastric cancer developed before 2015. The risk increased with duration of PPI use (Hazard ratio 5.0, 6.7, and 8.3 for ≥ 1, 2, and 3 years, respectively). Many re searchers quickly responded to this topic, and both affirming [67] and contradicting reports [68, 69] followed this paper. Interestingly, another populationbased study in Sweden also indicated the increased risk of gastric cancer (regardless of H. pylori infection or eradication) in maintenance therapy with PPI [70] . Contrary to the former study on H. pylori-eradicated cases [57] , this study did not find that the risk increased with therapeutic duration. Therefore, this topic still requires more study before a consensus can be reached, but clinicians should take PPI use into account for future studies of gastric cancer risk assessment.
Other
Age factor has also been reported in many studies. Most studies showed an older age at eradication is associated with an increased risk of developing cancer in univariate analysis [31, 55, 59] . However, age is also closely associated with other gastritisrelated phenotypes, which often lead to less value in carcinogenesis under multivariate analysis. For example, a cohort study examined 101 his tologically diagnosed corpus atrophic gastritis patients who underwent successful eradication therapy [58] . This study found eight gastric cancer cases (all intestinal type) during a mean followup period of 5.3 year, and the patients' characteristics and serum biochemistry data were compared in the groups with and without cancer. Out of age, sex, the disease indicated for eradi cation (gastritis or gastric ulcer), prior gastric cancer, pepsinogen value, and gastrin value, only age (64 years vs 55 years) was statistically different between groups. However, lack of multivariate analysis or other important confounding factors, such as endoscopic atrophy or his tological metaplasia, might have led to an immature con clusion in this study.
Endoscopic diagnosis associated with H. pylori infection has been examined as a risk or protective factor for gastric cancer development. In a H. pyloripersistent infection cohort, reduced risk for gastric cancer development was found specifically in duodenal ulcer patients (0 out of 275 for duodenal ulcer vs 36 out of 971 for other diseases) [10] . As for patients after eradication therapy, Kamada et al [41] reported that no gastric cancer developed in 654 duodenal ulcer patients, while 12 of 575 (2.1%), two of 453 (0.4%), and six of 105 (5.7%) cases were reported in gastric ulcer, atrophic gastritis and endoscopic resection for early gastric cancer patients, respectively. Kodama et al [59] . also reported only three gastric cancer cases, developed from 655 patients with duodenal ulcers (0.5%), while 10 of 902 (1.1%), 14 of 593 (2.4%), and 3 of 51 (5.9%) cases developed from patients with chronic gastritis, gastric ulcers, and gastric cancer, respectively. These reports indicate duodenal ulcer patients who received eradication therapy have less risk for future gastric cancer occurrence than do patients who have undergone eradication for other H. pylori related diseases.
Pepsinogen (PG) methods are clinically used for the gastriccancer screening program in Japan. As low PGI levels and low PGI/Ⅱ ratios are correlated with mucosal atrophy, the efficacy of this screening method for identifying highrisk subjects of gastric cancer has been reported in multiple cohort studies [71, 72] . However PG values and ratios change after H. pylori eradication [73] , and the usefulness of the PG method in H. pylorieradicated patients was not evident. Haneda et al [62] . examined PG levels in posteradication cases with and without gastric cancer, and found that the optimal cutoff value for the PGI/Ⅱ ratio was 4.5 (instead of the usual 3.0). The usefulness of this cutoff value in clinical practice needs to be confirmed in a cohort or a prospective study.
Finally, molecular indicators of gastric cancer risk have been investigated intensively. Recent research, focused on epigenetic markers, has revealed completely new types of gastric cancer risk predictors. In a case control study consisting of eight cases without infection, 75 atrophic gastritis posteradication cases and 94 gastric cancer posteradication cases, nine candidate epigenetic markers, which showed elevated methylation levels in cancer cases, were isolated [63] . These new markers are now being evaluated in a prospective cohort study, which will elucidate the clinical usefulness of these molecular approaches in the near future.
PERSPECTIvES
Here we have reviewed characteristics and predictors of gastric cancer after H. pylori eradication. Knowledge of endoscopic characteristics, such as depressed and gastritislike appearance, and an understanding of the histological nonneoplastic epithelium, will be helpful in detecting gastric cancer while screening subjects after eradication therapy. Reportedly, the tumors detected after H. pylori eradication seemed to be less proliferative and more gastric phenotype. This might be associated with a differentiation program by adulttissue stem cells, and the mechanism of these molecular changes and the effect of H. pylori eradication will be an interesting research project. As for predictors, severe endoscopic atrophy, histologic intestinal metaplasia before era dication, and PPI use are reportedly risk factors for gastric cancer development after eradication. Cases with these risk factors should be carefully followed up by endoscopy, with special attention paid to the afore mentioned characteristic endoscopic findings.
So far, most of the risk factors were evaluated be fore the eradication, which is helpful for identifying highrisk patients early so they can be invited into a surveillance program. However, risk stratification ac cording to findings after eradication, not those before eradication, might be more practical, because infor mation prior to eradication is not always available. For example, we proposed that histological intestinal metaplasia is an important risk factor for future gas tric cancer development, but most of the H. pylorieradicated subjects in the community did not receive a histological evaluation prior to eradication. If there is little change in the metaplasia after eradication, then assessment of histology after eradication may be used as a substitute, but this would need to be evaluated by independent studies. Risk stratification by pepsinogen levels after eradication has been reported [62] , but fur ther validation studies are necessary. Some researchers have focused on endoscopic changes after H. pylori eradication that was accompanied with cancer [74] . Map like redness after eradication, which corresponds to intestinal metaplasia histologically, could be a predictor for metachronous gastric cancer. Importantly, recent retrospective epigenetic research used gastric samples collected from posteradication cases, which is ideally applicable to all subjects [63] . Therefore the result of the ongoing prospective study is highly anticipated.
Eradication therapy is relatively new, and current stu dies are mostly limited to elder patients over 50 years old. Therefore, further longterm followup studies, over several decades, or a study of the young population should be required to form a consensus for an adequate surveillance program. Based on the results reviewed in this paper, it is safe to propose annual endoscopic surveillance for highrisk H. pylorieradicated patients, such as those with severe endoscopic atrophic gastritis (O2 or O3) or histological intestinal metaplasia before eradication. Patients who require PPI treatment for any reason after eradication should also have an annual checkup for both gastric cancer surveillance and for the conditions requiring PPI. However, for other relatively lowrisk eradicated patients, such as subjects with mild atrophy or no metaplasia, little evidence exists to propose a proper surveillance program. As these relatively low risk patients consist of the majority of H. pylori-eradicated cases, studies targeting these subjects will definitely be required. New studies, new modalities, and new concepts will lead to the establishment of a primary gastric cancer surveillance program suitable for all H. pylori-eradicated cases according to their cancer risk stratification.
CONCLUSION
In this review article, we have summarized the previous studies on the characteristics and predictors of gastric cancer which developed after successful H. pylori eradi cation. Gastric cancer surveillance program after H. pylori eradication according to risk stratification needs to be established in future.
